Deafness, Autosomal Recessive 9: Clinical Trials

6 trials for Deafness, Autosomal Recessive 9, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 active not recruiting, 1 enrolling by invitation, 1 not yet recruiting. 2 Phase 1, 2 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 12Active not recruiting 1, Recruiting 1
Phase 22Active not recruiting 1, Recruiting 1
Phase 31Recruiting 1

Follow Deafness, Autosomal Recessive 9: new trials by email Literature Review of Deafness, Autosomal Recessive 9 trials Research Report on Deafness, Autosomal Recessive 9

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Genetic Study of OTOF- Related Auditory Neuropathy Spectrum Disorder
Whole exome sequencing. - Auditory Neuropathy Spectrum Disorder, Auditory Neuropathy
Not yet recruitingSohag University302026-08-012026-08-21
A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations
Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF), Biallelic Mutations in the Gap Junction Beta 2 (GJB2) Gene
WithdrawnRegeneron Pharmaceuticals2025-06-302025-05-15
Long Term Follow-up Study of AAVAnc80-hOTOF Gene Therapy
Otoferlin Gene-mediated Hearing Loss
Enrolling by invitationEli Lilly and Company302024-11-112026-11-04
A Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations
SENS-501 administration - OTOF Gene Mutation, DFNB9
Phase 1 / Phase 2Active not recruitingSensorion122024-06-212026-07-08
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
AAVAnc80-hOTOF via Akouos Delivery Device, AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism - Sensorineural Hearing Loss, Bilateral
Phase 3RecruitingEli Lilly and Company482023-09-152026-09-29
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
DB-OTO - Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Phase 1 / Phase 2RecruitingRegeneron Pharmaceuticals362023-06-272026-08-05

Narrower conditions

Auditory neuropathy (5)  ·  Hearing Loss (5)  ·  Hearing Loss, Sensorineural (5)  ·  Deafness (3)  ·  Hearing Disorders (3)  ·  Hearing Loss, Bilateral (2)  ·  Ear Diseases (1)  ·  Hearing Loss, Hidden (1)  ·  Otorhinolaryngologic Diseases (1)

Broader conditions

Nervous System Diseases (6)  ·  Neurologic Manifestations (6)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Sensation Disorders (6)  ·  Signs and Symptoms (6)  ·  Ear Diseases (5)  ·  Otorhinolaryngologic Diseases (5)  ·  Hearing Disorders (3)  ·  Hearing Loss (1)

Interventions

Exome (1)  ·  OTOF protein, human (1)

Sponsors

Eli Lilly and Company (2)  ·  Regeneron Pharmaceuticals (2)  ·  Sensorion (1)  ·  Sohag University (1)

Countries

United States (4)  ·  Spain (2)  ·  Taiwan (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Canada (1)  ·  Egypt (1)  ·  France (1)  ·  Germany (1)  ·  Japan (1)

Top investigators

Sarah Neuhaus, D.O. (2)

Results publications

PMID 41085057, PMID 12809326, PMID 19409623, PMID 22939890, PMID 26818607, PMID 27340636, PMID 27729456, PMID 28696301, PMID 29111973, PMID 29688962, PMID 30482216, PMID 31453354, PMID 33908410, PMID 34424407, PMID 36769387, PMID 37679651, PMID 42279121

NIH funding

2023 (1)